IL6 and familial pancreatic carcinoma: Although drugs preventing IL‐6 signalling, such as suramin, tocilizumab or MR16‐1, inhibited C26‐,37 pancreatic cancer‐35 or LLC‐induced38 cachexia in mice, studies in humans were less convincing,38, 39 suggesting that in humans, a multifactorial systemic disease like CAC cannot be treated solely by targeting IL‐6 but by angling multiple mechanisms.